We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Serosep Ltd. is one of Ireland’s leading diagnostics specialists and an innovative, specialist partner of choice for ... read more Featured Products: More products

Download Mobile App

New Tests to Help Predict Disease Progression in Ulcerative Colitis

By LabMedica International staff writers
Posted on 24 Jan 2024
Print article
Image: The new partnership is set to personalize treatment for ulcerative colitis (Photo courtesy of RCSI)
Image: The new partnership is set to personalize treatment for ulcerative colitis (Photo courtesy of RCSI)

Ulcerative colitis, a type of inflammatory bowel disease, progressively damages the gut lining. It leads to inflammation and ulcers in the colon and rectum. Currently, the initial treatment for mild-to-moderate cases typically involves 5-Aminosalicylates (5-ASA), while more advanced stages are managed with steroids, immunosuppressants, and biological drugs. There is an urgent need for accurate biomarker-based methods to quickly identify the most effective treatment plans post-diagnosis. Now, a new collaboration aims to personalize treatments for ulcerative colitis, ultimately enhancing the quality of life for those affected by the condition.

RCSI University of Medicine and Health Sciences (Dublin, Ireland) and diagnostics company Serosep Ltd. (Limerick, Ireland) have joined forces to expedite the development of innovative tests to predict disease progression in individuals with ulcerative colitis. This initiative will focus on developing technology to identify patients whose condition is likely to worsen. The goal is to ensure individuals receive the most beneficial care for their specific disease stage while avoiding unnecessary treatments.

The partnership will concentrate on validating specific biomarkers for ulcerative colitis, initially identified by the RCSI group in laboratory settings. The aim is to establish a new in-vitro diagnostic tool that will aid clinicians in making informed decisions about the best treatment options for their patients. The tool will be based on a panel of measurable and trackable biomarkers in tissue samples and potentially in blood samples.

“Currently there are no biomarkers which allow prediction of disease progression in patients with ulcerative colitis,” said Dr. Sudipto Das, Lecturer and Principal Investigator at RCSI School of Pharmacy and Biomolecular Sciences. “Having such biomarkers could augment decision-making for clinicians about whether the patient could benefit from an escalation of treatment at an early stage of the disease.”

“Through recent work in our lab we have identified specific genes that can potentially predict disease progression in adult ulcerative colitis patients,” added Dr. Das. “This partnership will allow us to further validate these genes in a larger cohort of patient samples and enable development of a test that can be applied in the clinic to identify patients who are likely to progress at an early stage of disease. This in turn would allow early treatment for those patients, and sparing patients who are less likely to progress from unnecessary treatment. The ultimate impact of this test would be to improve quality of life in patients with ulcerative colitis.”

Related Links:
Serosep Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Clinical Chemistry

view channel
Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)

Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases

The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more


view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.